Thomas Chun, MD
Urology · Cliffside Park, NJNPI 1407846827
Payments from drug & device makers
Across 231 payments — averaging $45.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$3K
- Neotract Inc.$3K
- Teleflex LLC$1K
- Astellas Pharma US Inc$541
- Medtronic$409
- Sumitomo Pharma America, Inc.$374
- plus $2K from 32 others
What the payments were for
- Travel & lodging$5,01048%
- Food & beverage$5,06948%
- Education$4254%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 35 | $3,192 |
| Neotract Inc. | 43 | $2,736 |
| Teleflex LLC | 14 | $1,221 |
| Astellas Pharma US Inc | 20 | $541 |
| Medtronic(2 entities) | 12 | $409 |
| Sumitomo Pharma America, Inc. | 15 | $374 |
| Boston Scientific | 4 | $291 |
| Pfizer | 8 | $194 |
| Myovant Sciences Inc. | 11 | $148 |
| Myriad Genetic Laboratories, Inc. | 6 | $116 |
| Bayer | 6 | $114 |
| Urogen Pharma, Inc. | 1 | $114 |
| Koelis Inc. | 1 | $99 |
| Bard Access Systems, Inc. | 2 | $82 |
| Bluewind Medical | 3 | $80 |
| AbbVie | 5 | $64 |
| Dendreon Pharmaceuticals LLC | 4 | $63 |
| AstraZeneca | 4 | $59 |
| Tolmar, Inc. | 3 | $54 |
| Endo Pharmaceuticals Inc. | 4 | $51 |
| Amgen | 3 | $46 |
| Merck | 3 | $45 |
| Olympus America Inc. | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 3 | $42 |
| Dentsply IH Inc. | 2 | $40 |
| Rochester Medical Corporation | 2 | $39 |
| Travere Therapeutics, Inc. | 2 | $37 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $30 |
| Tolmar Pharmaceuticals, Inc. | 2 | $26 |
| Coloplast | 1 | $22 |
| Metuchen Pharmaceuticals | 1 | $20 |
| ABC Home Medical Supply, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Procept Biorobotics Corporation | 1 | $17 |
| GSK | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Hollister Incorporated | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,504 in reported general payments places this provider in the 80th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 370 | $221,064 |
| OrgovyxRelugolix | 23 | $56,431 |
| GemtesaVibegron | 61 | $43,773 |
| Tamsulosin Hcl | 652 | $10,590 |
| Dutasteride | 173 | $6,224 |
| Finasteride | 448 | $6,033 |
| Cefpodoxime Proxetil | 28 | $1,973 |
| Potassium Citrate ErPotassium Citrate | 25 | $1,891 |
| Silodosin | 24 | $1,799 |
| Oxybutynin Chloride ErOxybutynin Chloride | 59 | $1,780 |
| Solifenacin Succinate | 30 | $1,607 |
| Bethanechol Chloride | 24 | $1,269 |
| NitrofurantoinNitrofurantoin Macrocrystal | 30 | $1,197 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 38 | $1,173 |
| Ciprofloxacin Hcl | 160 | $868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $541 | $221,064370 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $374 | $100,20484 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 401 urology providers in New Jersey.
Other urology in Cliffside Park
- Eric MargolisCliffside Park$177K
- Robert SimonCliffside Park$108K
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Michael IngberDenville$607K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.